To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".
Already a subscriber? Enter your email address below and click "Find" to look up and manage your current contact details and subscription preferences.
Single-lesion biopsy may be insufficient to choose therapy targeting resistance mutations
When metastatic tumors driven by drug-targetable genetic mutations become resistant to a targeted therapy drug, the usual practice is to biopsy a single metastatic lesion to test for new mutations…
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for… Source link